Rochester,NY 8/18/2009 1:40:02 AM
AEterna Zentaris Inc. (USA) , AEZS - AEterna Zentaris Announces Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia announced
AEterna Zentaris Inc. (USA)
A global biopharmaceutical company AEterna Zentaris Inc. focused on endocrine therapy and oncology, reported today that the Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Sign up for our free alerts newsletter.
With its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
